* Says 2009 net loss to rise due to drug launch expenses
* To report 2009 results on or before March 31
March 22 Spectrum Pharmaceuticals Inc (SPPI.O)
said its net loss for 2009 may rise significantly due to higher
sales and marketing expenses, including payroll costs, incurred
with the launch of two drugs -- Zevalin and Fusilev.
In a regulatory filing, the company said it would report
the net loss when it has finalized its financial statements for
the year, on or before March 31.
Zevalin is indicated for the treatment of patients with
previously untreated follicular non-Hodgkin's lymphoma, while
Fusilev, which was launched in late 2008, helps to protect
healthy cells in patients after a high dose of chemotherapy for
the treatment of bone cancer.
The company had posted a net loss of $15.5 million for
Shares of the company were down marginally at $5.09 Monday
morning on Nasdaq.
(Reporting by Esha Dey in Bangalore)